Additional Notes - Summary of Contingent Liabilities - Narrative (Details) - Contingent liabilities € in Millions, $ in Millions	12 Months Ended
Dec. 31, 2023 EUR (€)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 EUR (€)
Disclosure of contingent liabilities [line items]
Milestone payment		$ 236.5	€ 214.0
Deferred income from obligations to royalty pharma	€ 786.4
Contingent liabilities incurred in relation to interests in associates	€ 226.8

The amount of contingent liabilities incurred relating to the entity's interests in associates. [Refer: Associates [member]; Contingent liabilities [member]]

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2023-01-01
-Paragraph 23
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_23_b&doctype=Standard
-URIDate 2023-03-23

Name:	ifrs-full_ContingentLiabilitiesIncurredInRelationToInterestsInAssociates
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant